Powder: -20°C for 3 years | In solvent: -80°C for 1 year
c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,270.00 | |
50 mg | 10-14 weeks | $ 2,980.00 | |
100 mg | 10-14 weeks | $ 4,000.00 |
Description | c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity. |
Targets&IC50 | c-Met:0.6 nM |
In vitro | c-Met-IN-2 (Compound 14) also shows weak activity on other kinases, with IC50s of 731 nM (RON), 1075 nM (AxI), 18364 nM (VEGFR2), 2357 nM (PDGFRa), 5396 nM (c-Kit), 17056 nM (c-Src). |
In vivo | In mice bearing H1993 tumors, c-Met-IN-2 (0.1, 1, 10 mg/kg, p.o., once daily) significantly reduces the volume of tumors. c-Met-IN-2 has a similar effect in SNU-5 xenograft model via oral administration at 0.3, 1 and 3 mg/kg. |
Molecular Weight | 484.49 |
Formula | C24H21FN10O |
CAS No. | 1635406-73-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
c-Met-IN-2 1635406-73-3 Tyrosine Kinase/Adaptors c-Met/HGFR c Met IN 2 cMetIN2 inhibitor inhibit